A single-cell analysis of nearly half a million cells from 62 pancreatic tumors shows how cancer cells keep reshaping their genetic activity over time, helping some clones resist therapy and others spread.
Stanford Medicine researchers designed a two-headed molecule that rewires BCL6, a common driver of B-cell lymphoma, so that instead of silencing cell death genes it switches them on. In mice, aggressive tumors were gone within 11 days.
A small randomized trial shows that paricalcitol, an FDA-approved vitamin D analog, can be added safely to chemotherapy and reprogram the fibroblast-rich shield around pancreatic tumors, building on years of research at the Salk Institute.
A new WashU Medicine study links accelerated biological aging in younger generations to rising rates of early-onset cancer — with immune aging tied to lung cancer and fat-tissue aging tied to colorectal cancer.
Personalized cell therapies have transformed cancer treatment for some patients, but they share a common problem: each dose has to be custom-built from that patient's own cells, a process that can take weeks and cost hundreds of thousands of dollars.... Continue Reading →
We've all heard "sitting is the new smoking" but a massive new UK Biobank study, just published in PLOS Medicine, suggests the real story is more nuanced: it's not sitting itself that raises cancer risk, it's sitting uninterrupted for long... Continue Reading →
Glioblastoma has a grim reputation among brain cancers, and for good reason. It tends to weave itself into surrounding healthy brain tissue, which makes complete surgical removal nearly impossible without risking damage to areas surgeons need to protect. The blood-brain... Continue Reading →